Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT07281976 Clinical Landscape Report 2026
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT07281976 Clinical Landscape Report 2026
18 September 2026
NCT07281976 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Nivolumab in Liver metastases: NCT07281924 Clinical Landscape Report 2026
9 min read
Nivolumab in Liver metastases: NCT07281924 Clinical Landscape Report 2026
18 September 2026
NCT07281924 clinical landscape for Liver metastases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Dexmedetomidine Hydrochloride in Sarcoma: NCT07276867 Clinical Landscape Report 2026
9 min read
Dexmedetomidine Hydrochloride in Sarcoma: NCT07276867 Clinical Landscape Report 2026
18 September 2026
NCT07276867 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Zamtocabtagene autoleucel in Carney Complex: NCT07288879 Clinical Landscape Report 2026
9 min read
Zamtocabtagene autoleucel in Carney Complex: NCT07288879 Clinical Landscape Report 2026
18 September 2026
NCT07288879 clinical landscape for Carney Complex: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Aspirin in Pain: NCT07281547 Clinical Landscape Report 2026
9 min read
Aspirin in Pain: NCT07281547 Clinical Landscape Report 2026
18 September 2026
NCT07281547 clinical landscape for Pain: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Mocertatug Rezetecan in Endometrial Carcinoma: NCT07286331 Clinical Landscape Report 2026
9 min read
Mocertatug Rezetecan in Endometrial Carcinoma: NCT07286331 Clinical Landscape Report 2026
18 September 2026
NCT07286331 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ruxolitinib Phosphate in Peripheral T-Cell Lymphoma: NCT07283822 Clinical Landscape Report 2026
9 min read
Ruxolitinib Phosphate in Peripheral T-Cell Lymphoma: NCT07283822 Clinical Landscape Report 2026
18 September 2026
NCT07283822 clinical landscape for Peripheral T-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Pembrolizumab in Metastatic Soft Tissue Sarcoma: NCT07283731 Clinical Landscape Report 2026
9 min read
Pembrolizumab in Metastatic Soft Tissue Sarcoma: NCT07283731 Clinical Landscape Report 2026
18 September 2026
NCT07283731 clinical landscape for Metastatic Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
AVC-203 in Relapsing acute myeloid leukemia: NCT07284433 Clinical Landscape Report 2026
9 min read
AVC-203 in Relapsing acute myeloid leukemia: NCT07284433 Clinical Landscape Report 2026
18 September 2026
NCT07284433 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
Read →
Serplulimab in Triple Negative Breast Cancer: NCT07283692 Clinical Landscape Report 2026
9 min read
Serplulimab in Triple Negative Breast Cancer: NCT07283692 Clinical Landscape Report 2026
18 September 2026
NCT07283692 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Lifileucel in Melanoma, Cutaneous Malignant: NCT07288203 Clinical Landscape Report 2026
9 min read
Lifileucel in Melanoma, Cutaneous Malignant: NCT07288203 Clinical Landscape Report 2026
18 September 2026
NCT07288203 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Dubodencel in Refractory Melanoma: NCT07288112 Clinical Landscape Report 2026
9 min read
Dubodencel in Refractory Melanoma: NCT07288112 Clinical Landscape Report 2026
18 September 2026
NCT07288112 clinical landscape for Refractory Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →